Summary
We have reviewed the ability of gene expression microarrays to characterize subgroups of lymphoma and leukemia, identify expression profiles that correlate with known cytogenetic abnormalities, demonstrate that expression profiles can predict prognosis, new proteins identified for diagnosis and followup, and provided new therapeutic targets for chemotherapy. We can expect that new prognostic models will be designed and tested, incorporating the pathologic diagnosis based on morphology, the molecular gene expression profile, and the clinical assessment (e.g. International prognostic index). In addition, the gene expression profiles will be used to generate correlative and ultimately predictive data for response to particular chemotherapeutic regimens. Translation for clinical usage is likely in a diagnostic fashion in both lymphoma and leukemia.32–35
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Wellmann A et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 2000; 96(2): 398–404.
Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol 2002; 118(5): 773–779.
Saffer H et al., Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod Pathol 2002; 15(11): 1221–1226.
Golub TR et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286(5439): 531–537.
Alizadeh AA et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403(6769): 503–511.
Alizadeh, A et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999; 64: 71–78.
Hofmann, WK et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100(10): 3553–3560.
Husson H et al., Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99(1): 282–289.
Rosenwald A et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346(25): 1937–1947.
Nishiu M et al. Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: Identification of genes related to disease progression. Jpn J Cancer Res 2002; 93:894–901.
Ek S et al. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002; 62(15): 4398–4405.
Shipp MA et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8(1): 68–74.
Rosenwald A et al. The Proliferation Gene Expression Signature is a Quantitative Integrator of Oncogenic Events That Predicts Survival in Mantle Cell Lymphoma. Cancer Cell 2003; in press.
Huang JZ et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99(7): 2285–2290.
Losses IS et al., Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-likediffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97(18): 10209–10213.
Davis RE et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194(12): 1861–1874.
Hofmann WK et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98(3): 787–794.
Korz C et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 2002; 99(12): 4554–4561.
Zhu Y et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 2002; 119(4): 905–915.
de Vos S et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003; 83(2): 271–285.
Virtaneva K et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001; 98(3): 1124–1129.
Schoch, C., et al., Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002; 99(15): 10008–10013.
Moos PJ et al. Identification of gene expression profiles that segregate patients with childhood leukemia. Clin Cancer Res 2002; 8(10): 3118–3130.
Miyazato A et al. Identification of myelodysplastic syndrome-specificgenes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001; 98(2): 422–427.
Chen JS et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97(7): 2115–2120.
De Waele M et al. Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts. Eur J Haematol 1999; 63(3): 192–201.
Yeoh EJ et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1(2): 133–143.
Armstrong SA et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30(1): 41–47.
Klein U et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194(11): 1625–1638.
Rosenwald A et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194(11): 1639–1647.
Wiestner A et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101(12): 4944–4951.
Mohr S et al. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002; 20(14): 3165–3175.
Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. J Clin Oncol 2002; 20(7): 1932–1941.
Staudt LM. Gene expression profiling of lymphoid malignancies. Annu Rev Med 2002; 53: 303–318.
Chan WC, Huang JZ. Gene expression analysis in aggressive NHL. Ann Hematol 2001; 80(Suppl 3): B38–41.
Stratowa C et al. cDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Caner 2001; 91(4): 474–480.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Greiner, T.C. (2004). mRNA Microarray Analysis in Lymphoma and Leukemia. In: Finn, W.G., Peterson, L.C. (eds) Hematopathology in Oncology. Cancer Treatment and Research, vol 121. Springer, Boston, MA. https://doi.org/10.1007/1-4020-7920-6_1
Download citation
DOI: https://doi.org/10.1007/1-4020-7920-6_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7919-1
Online ISBN: 978-1-4020-7920-7
eBook Packages: Springer Book Archive